JP2022008641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022008641A5 JP2022008641A5 JP2021159462A JP2021159462A JP2022008641A5 JP 2022008641 A5 JP2022008641 A5 JP 2022008641A5 JP 2021159462 A JP2021159462 A JP 2021159462A JP 2021159462 A JP2021159462 A JP 2021159462A JP 2022008641 A5 JP2022008641 A5 JP 2022008641A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- level
- sample
- fold
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972091P | 2014-03-28 | 2014-03-28 | |
| US61/972,091 | 2014-03-28 | ||
| PCT/US2015/023038 WO2015148950A1 (en) | 2014-03-28 | 2015-03-27 | L-2-hydroxyglutarate and stress induced metabolism |
| JP2017502940A JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Division JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022008641A JP2022008641A (ja) | 2022-01-13 |
| JP2022008641A5 true JP2022008641A5 (enExample) | 2022-02-14 |
| JP7208323B2 JP7208323B2 (ja) | 2023-01-18 |
Family
ID=54196451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Expired - Fee Related JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
| JP2021159462A Active JP7208323B2 (ja) | 2014-03-28 | 2021-09-29 | Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Expired - Fee Related JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10450596B2 (enExample) |
| EP (1) | EP3122893B1 (enExample) |
| JP (2) | JP6953305B2 (enExample) |
| AU (1) | AU2015237241B2 (enExample) |
| CA (1) | CA2943823C (enExample) |
| WO (1) | WO2015148950A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012340192B2 (en) | 2011-11-18 | 2016-04-07 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
| US10450596B2 (en) | 2014-03-28 | 2019-10-22 | Memorial Sloan-Kettering Cancer Center | L-2-hydroxyglutarate and stress induced metabolism |
| CA3053356A1 (en) * | 2017-02-10 | 2018-08-16 | Health Research, Inc. | Targeting mitochondrial complex ii to reduce effects of chronic hypoxia |
| US10500318B1 (en) * | 2018-07-03 | 2019-12-10 | Temple Therapeutics BV | Dosing regimens for treating hypoxia-associated tissue damage |
| JP6977999B2 (ja) * | 2018-08-22 | 2021-12-08 | 国立大学法人京都大学 | 胚培養培地、及び胚培養方法 |
| FR3097739B1 (fr) * | 2019-06-25 | 2022-03-04 | Lnc Therapeutics | Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate |
| CN112830958B (zh) * | 2021-02-05 | 2022-06-14 | 山东大学 | 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US20060084123A1 (en) | 2001-12-13 | 2006-04-20 | Harris Adrian L | MN and hypoxia |
| AU2003302132B2 (en) * | 2002-11-21 | 2008-02-21 | Inverness Medical Switzerland Gmbh | Bodily fluid markers of tissue hypoxia |
| US20090186358A1 (en) | 2007-12-21 | 2009-07-23 | Wyeth | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof |
| EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| SE534542C2 (sv) | 2009-09-30 | 2011-09-27 | Calmark Sweden Ab | Testsystem för bestämning av hypoxiutlöst cellskada |
| WO2011050211A2 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US20120202883A1 (en) | 2011-01-20 | 2012-08-09 | Duke University | Effects of idh1 and idh2 mutations on the cellular metabolome |
| AU2012340192B2 (en) | 2011-11-18 | 2016-04-07 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
| EP2788763A4 (en) * | 2011-12-09 | 2015-10-07 | Metabolon Inc | BIOMARKERS FOR RENAL CANCER AND METHODS OF USE |
| US8977473B2 (en) | 2012-08-29 | 2015-03-10 | Caterpillar Inc. | Pressure control strategy for dual fuel compression ignition engine and machine using same |
| US10450596B2 (en) | 2014-03-28 | 2019-10-22 | Memorial Sloan-Kettering Cancer Center | L-2-hydroxyglutarate and stress induced metabolism |
-
2015
- 2015-03-27 US US15/129,167 patent/US10450596B2/en active Active
- 2015-03-27 AU AU2015237241A patent/AU2015237241B2/en not_active Ceased
- 2015-03-27 EP EP15768552.0A patent/EP3122893B1/en active Active
- 2015-03-27 JP JP2017502940A patent/JP6953305B2/ja not_active Expired - Fee Related
- 2015-03-27 WO PCT/US2015/023038 patent/WO2015148950A1/en not_active Ceased
- 2015-03-27 CA CA2943823A patent/CA2943823C/en active Active
-
2019
- 2019-06-25 US US16/452,297 patent/US11788112B2/en active Active
-
2021
- 2021-09-29 JP JP2021159462A patent/JP7208323B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022008641A5 (enExample) | ||
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP2017520774A5 (enExample) | ||
| Franciosi et al. | Susceptibility to COPD: differential proteomic profiling after acute smoking | |
| Palmiere et al. | Endocan measurement for the postmortem diagnosis of sepsis | |
| Wu et al. | Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients | |
| JP2025019061A (ja) | 術後有害事象の診断または予後 | |
| JP2017519523A (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Nakamura et al. | Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock | |
| Fang et al. | Asymmetric dimethyl-L-arginine is a biomarker for disease stage and follow-up of pulmonary hypertension associated with congenital heart disease | |
| Kotlinska-Hasiec et al. | Disturbance in venous outflow from the cerebral circulation intensifies the release of blood-brain barrier injury biomarkers in patients undergoing cardiac surgery | |
| JP2024023615A (ja) | 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ | |
| Gamil et al. | Increased serum levels of asymmetric dimethylarginine and symmetric dimethylarginine and decreased levels of arginine in sudanese patients with essential hypertension | |
| Kališnik et al. | Creatinine, Neutrophil Gelatinase‐Associated Lipocalin, and Cystatin C in Determining Acute Kidney Injury After Heart Operations Using Cardiopulmonary Bypass | |
| Wang | The function of S100A4 in pulmonary disease: A review | |
| Jain | Biomarkers of pulmonary diseases | |
| Morishima et al. | A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor | |
| Ding et al. | Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection | |
| CN116359515A (zh) | 检测和治疗肺高压的方法 | |
| US11634717B2 (en) | DNA aptamer specifically binding to TB7.7, and use thereof | |
| Adamik et al. | Inflammasome-related markers upon ICU admission do not correlate with outcome in critically Ill COVID-19 patients | |
| Lee et al. | Upregulation of Potassium Voltage‐Gated Channel Subfamily J Member 2 Levels in the Lungs of Patients with Idiopathic Pulmonary Fibrosis | |
| Bauer et al. | Systemic inflammatory response after bronchoalveolar lavage in critically ill patients | |
| JP2012521549A5 (enExample) | ||
| Tanaka et al. | Polymyxin B. Hemoperfusion improves hemodynamic status in patients with sepsis with both gram-negative and non-gram-negative bacteria |